Differential effects between cyclooxygenase-2 inhibitors and siRNA on vascular endothelial growth factor production in head and neck squamous cell carcinoma cell lines

Head and Neck

Volumn 32, Issue 11, 2010, Pages 1534-1543

  Park, Seok Woo ^a   Kim, Hyo Sun ^a   Hah, Jeong Hun ^a   Kim, Kwang Hyun ^a   Heo, Dae Seog ^a   Sung, Myung Whun ^a  

^a Seoul National University College of Medicine   (South Korea)

Author keywords

COX 1; COX 2; cyclooxygenase 2; small interfering RNA; VEGF

Indexed keywords

5 (4 CHLOROPHENYL) 1 (4 METHOXYPHENYL) 3 TRIFLUOROMETHYL 1H PYRAZOLE; 5 BROMO 2 (4 FLUOROPHENYL) 3 (4 METHYLSULFONYLPHENYL)THIOPHENE; CAY 10404; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; INDOMETACIN; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CELL GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; HEAD AND NECK CARCINOMA; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; INTRACELLULAR SIGNALING; PRIORITY JOURNAL; PROTEIN SECRETION; PROTEIN SYNTHESIS; SQUAMOUS CELL CARCINOMA;

CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; DINOPROSTONE; DOSE-RESPONSE RELATIONSHIP, DRUG; HEAD AND NECK NEOPLASMS; HUMANS; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 78649461901     PISSN: 10433074     EISSN: 10970347     Source Type: Journal    
DOI: 10.1002/hed.21362     Document Type: Article

References (27)

1. Eberhart CE, Coffey RJ, Radhika A, Giardiello FM, Ferrenbach S, DuBois RN,. Up-regulation of cyclooxygenase-2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 1994; 107: 1183-1188.
2. Lee DW, Sung MW, Park SW, et al. Increased cyclooxygenase-2 expression in human squamous cell carcinomas of the head and neck and inhibition of proliferation by nonsteroidal anti-inflammatory drugs. Anticancer Res 2002; 22: 2089-2096.
3. Brown JR, DuBois RN,. COX-2: a molecular target for colorectal cancer prevention. J Clin Oncol 2005; 23: 2840-2855.
4. Zhi YH, Liu RS, Song MM, et al. Cyclooxygenase-2 promotes angiogenesis by increasing vascular endothelial growth factor and predicts prognosis in gallbladder carcinoma. World J Gastroenterol 2005; 11: 3724-3728.
5. Muller-Decker K, Neufang G, Berger I, Neumann M, Marks F, Furstenberger G,. Transgenic cyclooxygenase-2 overexpression sensitizes mouse skin for carcinogenesis. Proc Natl Acad Sci U S A 2002; 99: 12483-12488.
6. Kinugasa Y, Hatori M, Ito H, Kurihara Y, Ito D, Nagumo M,. Inhibition of cyclooxygenase-2 suppresses invasiveness of oral squamous cell carcinoma cell lines via down-regulation of matrix metalloproteinase-2 and CD44. Clin Exp Metastasis 2004; 21: 737-745.
7. Wang Z,. The role of COX-2 in oral cancer development, and chemoprevention/ treatment of oral cancer by selective COX-2 inhibitors. Curr Pharm Des 2005; 11: 1771-1777.
8. Shao J, Evers BM, Sheng H,. Prostaglandin E2 synergistically enhances receptor tyrosine kinase-dependent signaling system in colon cancer cells. J Biol Chem 2004; 279: 14287-14293.
9. Shao J, Lee SB, Guo H, Evers BM, Sheng H,. Prostaglandin E2 stimulates the growth of colon cancer cells via induction of amphiregulin. Cancer Res 2003; 63: 5218-5223.
10. Sheng H, Shao J, Washington MK, DuBois RN,. Prostaglandin E2 increases growth and motility of colorectal carcinoma cells. J Biol Chem 2001; 276: 18075-18081.
11. Regan JW,. EP2 and EP4 prostanoid receptor signaling. Life Sci 2003; 74: 143-153.
12. Soh JW, Weinstein IB,. Role of COX-independent targets of NSAIDs and related compounds in cancer prevention and treatment. Prog Exp Tumor Res 2003; 37: 261-285.
13. Maier TJ, Schilling K, Schmidt R, Geisslinger G, Grösch S,. Cyclooxygenase-2 (COX-2)-dependent and -independent anticarcinogenic effects of celecoxib in human colon carcinoma cells. Biochem Pharmacol 2004; 67: 1469-1478.
14. Park SW, Lee SG, Song SH, et al. The effect of nitric oxide on cyclooxygenase-2 (COX-2) overexpression in head and neck cancer cell lines. Int J Cancer 2003; 107: 729-738.
15. Elder DJ, Halton DE, Playle LC, Paraskeva C,. The MEK/ERK pathway mediates COX-2-selective NSAID-induced apoptosis and induced COX-2 protein expression in colorectal carcinoma cells. Int J Cancer 2002; 99: 323-327.
16. Maier TJ, Janssen A, Schmidt R, Geisslinger G, Grösch S,. Targeting the beta-catenin/APC pathway: a novel mechanism to explain the cyclooxygenase-2-independent anticarcinogenic effects of celecoxib in human colon carcinoma cells. Faseb J 2005; 19: 1353-1355.
17. Honjo S, Osaki M, Ardyanto TD, Hiramatsu T, Maeta N, Ito H,. COX-2 inhibitor, NS398, enhances Fas-mediated apoptosis via modulation of the PTEN-Akt pathway in human gastric carcinoma cell lines. DNA Cell Biol 2005; 24: 141-147.
18. Baek SJ, Wilson LC, Lee CH, Eling TE,. Dual function of nonsteroidal anti-inflammatory drugs (NSAIDs): inhibition of cyclooxygenase and induction of NSAID-activated gene. J Pharmacol Exp Ther 2002; 301: 1126-1131.
19. Daikoku T, Wang D, Tranguch S, et al. Cyclooxygenase-1 is a potential target for prevention and treatment of ovarian epithelial cancer. Cancer Res 2005; 65: 3735-3744.
20. Farivar-Mohseni H, Kandzari SJ, Zaslau S, Riggs DR, Jackson BJ, McFadden DW,. Synergistic effects of Cox-1 and -2 inhibition on bladder and prostate cancer in vitro. Am J Surg 2004; 188: 505-510. (Pubitemid 39491094)
21. Kino Y, Kojima F, Kiguchi K, Igarashi R, Ishizuka B, Kawai S,. Prostaglandin E2 production in ovarian cancer cell lines is regulated by cyclooxygenase-1, not cyclooxygenase-2. Prostaglandins Leukot Essent Fatty Acids 2005; 73: 103-111.
22. Warner TD, Giuliano F, Vojnovic I, Bukasa A, Mitchell JA, Vane JR,. Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. Proc Natl Acad Sci U S A 1999; 96: 7563-7568.
23. Charames GS, Bapat B,. Cyclooxygenase-2 knockdown by RNA interference in colon cancer. Int J Oncol 2006; 28: 543-549.
24. Denkert C, Furstenberg A, Daniel PT, et al. Induction of G0/G1 cell cycle arrest in ovarian carcinoma cells by the anti-inflammatory drug NS-398, but not by COX-2-specific RNA interference. Oncogene 2003; 22: 8653-8661.
25. Palayoor ST, Arayankalayil MJ, Shoaibi A, Coleman CN,. Radiation sensitivity of human carcinoma cells transfected with small interfering RNA targeted against cyclooxygenase-2. Clin Cancer Res 2005; 11: 6980-6986.
26. Park JW, Park JE, Lee JA, Lee CW, Kim CM,. Cyclooxygenase-2 (COX-2) is directly involved but not decisive in proliferation of human hepatocellular carcinoma cells. J Cancer Res Clin Oncol 2006; 132: 184-192.
27. Roh JL, Sung MW, Park SW, Heo DS, Lee DW, Kim KH,. Celecoxib can prevent tumor growth and distant metastasis in postoperative setting. Cancer Res 2004; 64: 3230-3235.